Article ID Journal Published Year Pages File Type
5583889 Seminars in Arthritis and Rheumatism 2017 36 Pages PDF
Abstract
Evidence from randomised trials suggests that most biological agents are effective as monotherapy. Although our confidence in the estimates is limited, etanercept or tocilizumab may be the optimal choice for most patients who need treatment with biological monotherapy. However, given our limited confidence in the estimates including possibility of bias, it is appropriate to strongly weight patients׳ preferences and values in the final treatment choice.
Related Topics
Health Sciences Medicine and Dentistry Anesthesiology and Pain Medicine
Authors
, , , , , , , , , , , , , , , , , , , , , , , , , ,